title: [Phase II study of docetaxel in inoperable advanced non small cell lung cancer].
abstract: The purpose is to determine the response to, and toxicity of docetaxel (Taxotère) in patients with inoperable non small cell lung cancer (NSCLC), previously untreated. Seventy patients with stage IIIB or IV NSCLC were treated by 100 mg/m2/ 3 weeks of docetaxel until tumor progression or severe toxicity. Premedication with diosmine and prednisolone was given in all patients: 66/70 were eligible and 55/70 were assessable for antitumoral activity. Median age: 63 years, WHO performans status 0-1: 83%, stage IV: 96%. For eligible patients, 17/66 (26%) achieved an objective response: 1 complete response and 16 partial response (IC 95% = 15-36). With a median follow-up of 23.4 months (range 14.9-28.7), for evaluable patients, the median response duration was 8 months, the median time to progression 4 months, and the median survival time 10 months. The median number of administered cycles is 5 (range 1-12). The estimate one year survival rate was 47%. Seventy-six patients presented neutropenia (grade 3-4); febrile neutropenia was observed in 7% of cycles. Non haematological toxicities are: fluid retention related to docetaxel (2.9%), diarrhea (6%), nausea-vomiting (4%), asthenia (3%), nail changes (6%). Docetaxel (Taxotère) administered at 100 mg/m2/3 weeks has relevant clinical activity in previously untreated NSCLC with a acceptable toxicity.
authors.affiliation: Service d'oncologie thoracique, Hôpital Morvan, 5, avenue Foch, 29609 Brest, France.
authors.forename: G
authors.initials: G
authors.lastname: Robinet
authors.forename: P
authors.initials: P
authors.lastname: Thomas
authors.forename: M
authors.initials: M
authors.lastname: Pérol
authors.forename: A
authors.initials: A
authors.lastname: Vergnenegre
authors.forename: H
authors.initials: H
authors.lastname: Lena
authors.forename: A
authors.initials: A
authors.lastname: Taytard
authors.forename: D
authors.initials: D
authors.lastname: Paillotin
authors.forename: E H
authors.initials: EH
authors.lastname: Bessa
authors.forename: M P
authors.initials: MP
authors.lastname: Schuller-Lebeau
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D043823:Taxoids
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel